Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. demonstrated a modest year-over-year growth in EsoGuard test volume, achieving 2,841 tests in Q3 2025, marking a 2% increase from the previous year and showing consistent quarterly growth. The company's proactive expansion of coverage for EsoGuard, including efforts with Medicare and private payers, positions it for substantial revenue growth as it enhances accessibility for a larger patient base. The recent positive developments from the MolDX CAC meeting and increased engagement with Medicare customers suggest a favorable outlook, highlighting the potential for significant revenue upside while balancing associated risks.

Bears say

Lucid Diagnostics Inc experienced a disappointing financial performance in 3Q25, as the company missed consensus revenue estimates while reporting a pro forma net loss of $10.3 million, reflecting ongoing financial challenges. The decline in EsoGuard test processing volumes, which fell from 3,034 in Q1 to 2,756 in Q2, indicates potential hurdles in market adoption and effectiveness of marketing strategies. Additionally, significant risks persist regarding reimbursement from insurers, competition from alternative tests, and overall liquidity concerns, all of which contribute to a negative outlook on the company's stock.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.